Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Haruo_Naito
|
| gptkbp:collaboratedWith |
gptkb:Biogen
|
| gptkbp:country |
gptkb:Japan
|
| gptkbp:focusArea |
gptkb:Alzheimer's_disease
neurology oncology |
| gptkbp:founded |
1941
|
| gptkbp:founder |
gptkb:Toyoji_Naito
|
| gptkbp:headquarters_location |
gptkb:Tokyo,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Eisai Group
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listedOn |
gptkb:Nikkei_225
|
| gptkbp:notable_drug |
gptkb:Leqembi
|
| gptkbp:numberOfEmployees |
~10,000
|
| gptkbp:officialWebsite |
https://www.eisai.com/
|
| gptkbp:parentCompany |
gptkb:Eisai_Co.,_Ltd.
|
| gptkbp:products |
gptkb:Lenvima
gptkb:Aricept gptkb:Fycompa gptkb:Halaven |
| gptkbp:revenue |
~700 billion yen (FY2023)
|
| gptkbp:servesArea |
worldwide
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stockSymbol |
4523
|
| gptkbp:subsidiary |
gptkb:Eisai_Inc.
|
| gptkbp:bfsParent |
gptkb:Eisai_Co.,_Ltd.
|
| gptkbp:bfsLayer |
6
|